Drug Delivery Devices - United States

  • United States
  • Revenue in the Drug Delivery Devices market market in the United States is anticipated to reach €13.92bn in 2024.
  • It is expected that revenue will demonstrate an annual growth rate (CAGR 2024-2029) of 4.84%.
  • This growth will lead to a projected market volume of €17.63bn by 2029.
  • In a global context, the in the United States is expected to generate the majority of revenue, amounting to €13.92bn in 2024.
  • The United States is witnessing a significant shift towards smart drug delivery devices, enhancing patient adherence and optimizing therapeutic outcomes in healthcare.
 
Mercado
 
Región
 
Comparación de regiones
 
Moneda
 

Analyst Opinion

The Drug Delivery Devices Market within the Medical Devices sector in the United States is experiencing mild growth, influenced by factors such as technological advancements, the rising prevalence of chronic diseases, and increasing demand for patient-centric healthcare solutions.

Customer preferences:
Consumers are increasingly favoring personalized drug delivery solutions that cater to individual health needs, resulting in a growing demand for smart inhalers and auto-injectors. The rise of telehealth services has also driven interest in devices that enable remote administration of medications, allowing patients to manage their conditions from home. Furthermore, the aging population is pushing for user-friendly designs and education on device usage, highlighting a preference for intuitive technology that enhances medication adherence and overall patient experience.

Trends in the market:
In the United States, the Drug Delivery Devices market is experiencing a surge in demand for personalized solutions, with smart inhalers and auto-injectors leading the charge. The integration of telehealth services is enhancing the appeal of devices that facilitate remote medication administration, empowering patients to manage their health from home. Additionally, the aging population is driving the need for user-friendly designs and educational resources, emphasizing intuitive technology that promotes medication adherence. These trends signify a shift toward patient-centric care, presenting significant opportunities for industry stakeholders to innovate and enhance the overall patient experience.

Local special circumstances:
In the United States, the Drug Delivery Devices market is shaped by diverse geographical and cultural factors, alongside stringent regulatory frameworks. The prevalence of chronic diseases and a focus on preventive care drive the demand for innovative drug delivery solutions. Furthermore, regional healthcare disparities highlight the need for accessible and effective devices, particularly in underserved areas. Cultural attitudes towards health management emphasize the importance of education and support, prompting manufacturers to create user-friendly devices that resonate with patients’ lifestyles, ultimately enhancing adherence and outcomes.

Underlying macroeconomic factors:
The Drug Delivery Devices market in the United States is significantly influenced by macroeconomic factors including national economic health, healthcare spending, and fiscal policies that prioritize innovation in medical technology. The ongoing shift towards value-based care encourages investment in advanced drug delivery solutions, while the rising prevalence of chronic diseases fuels demand for effective management tools. Furthermore, global economic trends, such as supply chain dynamics and technological advancements, impact production costs and accessibility. As health expenditures continue to rise, public and private sector funding for research and development enhances the competitive landscape, driving growth in the drug delivery devices sector.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

Visión general

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
Espere, por favor

Contacto

¿Alguna duda? Estaremos encantados de atenderte.
Statista Locations
Contacto Nerea Marcos
Nerea Marcos
Client Success Manager

Lu - vi, 9:30 - 17:00 h (CET)

Contacto Meredith Alda
Meredith Alda
Sales Manager– Contacto (Estados Unidos)

Lu - vi, 9:00 - 18:00 h (EST)

Contacto Yolanda Mega
Yolanda Mega
Operations Manager– Contacto (Asia)

Lu - vi, 9:00 - 17:00 h (SGT)

Contacto Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contacto (Asia)

Lu - vi, 10:00 - 18:00 h (JST)

Contacto Lodovica Biagi
Lodovica Biagi
Director of Operations– Contacto (Europa)

Lu - vi, 9:30 - 17:00 h (GMT)

Contacto Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contacto (América Latina)

Lu - vi, 9:00am-6:00pm (EST)